Referenzen
Produkte Transfektion
Kostenlose Testsamples
Anwendungshinweise:
Im „Transfection Reagent Selection Guide“ können Sie durch Filterfunktionen z.B. für Ihre Kombination aus zu transfizierender Zelle und Nukleinsäure die Liste vorhandener Referenzen durchsuchen. Ebenso können Sie im Feld „Referenzen durchsuchen“ am Anfang der Seite mit passenden Schlagwörtern zu einem Ergebnis gelangen. Eine Referenz zeigt an, dass das gefundene Transfektionsreagenz bereits erfolgreich für die entsprechende Anwendung verwendet wurde. Im Idealfall sind getestete Transfektionsparameter und Transfektionseffizienzen angegeben.
Keine Referenz? > Allgemeine Auswahlhilfe
Wenn Sie keine Referenz gefunden haben, heißt das nicht, dass kein passendes Reagenz zur Verfügung steht, sondern lediglich, dass bisher keine Erfahrungsberichte vorliegen. In diesem Falle kann durch eine Vorauswahl ein erfolgsversprechendes Transfektionsreagenz ausgewählt (Allgemeine Auswahlhilfe) und letztendlich ausgetestet (Kostenlose Testsamples) werden. Wenn Sie einen Erfahrungsbericht für uns schreiben möchten machen wir Ihnen ein Angebot für eine Gegenleistung.
CELL TYPE | DESCRIPTION OF CELL TYPE | CAT.NO. | SPECIES | ORIGIN OF CELLS | COMMON CELL TYPE | GROWTH PROPERTIES | NUCLEIC ACID / DELIVERED MOLECULE | APPLICATION | PRODUCT | REFERENCE TYPE | BIBLIOGRAPHIC DATA | LINK | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
HEK293 |
Human embryonic kidney cell line | ATCC CRL-1573 | Human | urinary system | cell line | adherent | plasmid | Metafectene PRO | publication | J. Kovalčíková et al., PhD Thesis, 2018, Univerzita Karlova | Link | ||
HEK293 |
Human embryonic kidney cell line | ATCC CRL-1573 | Human | urinary system | cell line | adherent | siRNA | RNA-Interference | Metafectene PRO | publication | S. Kim et al., Nature Communications, 2019, 10:4898, doi.org/10.1038/s41467-019-12910-2 | Link | |
HEK293 |
Human embryonic kidney cell line | ATCC CRL-1573 | Human | genital tract | cell line | adherent | plasmid | cotransfection (plasmid/plasmid) | Metafectene PRO | publication | J. Elvenes et al., PLoS ONE, 2011, 6(9): e24659, doi:10.1371/journal.pone.0024659 | Link | |
HEK293 |
Human embryonic kidney cell line | ATCC CRL-1573 | Human | urinary system | cell line | adherent | plasmid | Metafectene PRO | publication | F. Askarian et al., J. Innate Immun., 2014, 6: 485-498, DOI: 10.1159/000357618 | Link | ||
HEK293 |
Human embryonic kidney cell line | ATCC CRL-1573 | Human | urinary system | cell line | adherent | plasmid | Metafectene PRO | publication | L. Hoa et al., Cellular Signalling, 2016, 28: 488-497; doi.org/10.1016/j.cellsig.2016.02.012 | |||
HEK293 |
Human embryonic kidney cell line | ATCC CRL-1573 | Human | urinary system | cell line | adherent | plasmid | cotransfection (plasmid/plasmid) | Metafectene PRO | publication | S. Sperduti et al., Int. J. Mol. Sci., 2019, 20, 5548, doi:10.3390/ijms20225548 | Link | |
HEK293 |
Human embryonic kidney cell line | ATCC CRL-1573 | Human | urinary system | cell line | adherent | plasmid | Metafectene PRO | publication | M. A. Mazur et al., Diabetes, Aug 2013; 62: 2834 - 2842 | Link | ||
HEK293 |
Human embryonic kidney cell line | ATCC CRL-1573 | Human | urinary system | cell line | adherent | plasmid | Metafectene PRO | publication | N. Dominguez et al., FASEB J, Nov 2014; 28: 4657 - 4667 | |||
HEK293 |
Human embryonic kidney cell line | ATCC CRL-1573 | Human | urinary system | cell line | adherent | siRNA | RNA-Interference | Metafectene PRO | application note | ![]() |
||
HEK293 |
Human embryonic kidney cell line | ATCC CRL-1573 | Human | urinary system | cell line | adherent | siRNA | RNA-Interference | Metafectene PRO | publication | E. Werwein et al., Nucleic Acids Res., 2019, Vol. 47, 1: 103–121, doi: 10.1093/nar/gky935 | Link | |
HEK293 |
Human embryonic kidney cell line | ATCC CRL-1573 | Human | urinary system | cell line | adherent | plasmid | cotransfection (plasmid/plasmid) | Metafectene PRO | publication | J.-C. Park et al., 2017, US 2017/0100458 A1 | Link | |
HEK293 |
Human embryonic kidney cell line | ATCC CRL-1573 | Human | urinary system | cell line | adherent | plasmid | Metafectene PRO | publication | A. Trefier et al., The FASEB Journal, October 2017, article fj.201700763R, DOI: 10.1096/fj.201700763R | |||
HEK293 |
Human embryonic kidney cell line | ATCC CRL-1573 | Human | urinary system | cell line | adherent | plasmid | Metafectene PRO | publication | F. Seymen et al., J. Dental Res., Aug 2015; 94: 1063 - 1069 | |||
HEK293 (s) |
Human embryonic kidney cell line (suspension) | ATCC CRL-1573 | Human | urinary system | cell line | suspension | plasmid | Metafectene PRO | application note | ![]() |
|||
HEK293 EBNA |
Human embryonic kidney cell line stably expressing Epstein-Barr viral nuclear antigen (EBNA) (derivat of HEK293) | Human | urinary system | cell line | adherent | plasmid | antibody production | Metafectene PRO | application note | ![]() |
|||
HEK293 F |
Human embryonic kidney cell line (derivat of HEK293) | Human | urinary system | cell line | adherent | plasmid | Metafectene PRO | application note | ![]() |
||||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene PRO | publication | K. Klement et al., J. Cell Biol., Dec 2014; 207: 717 - 733 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene PRO | application note | ![]() |
|||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | bacmid | stable transfection | Metafectene PRO | publication | C. Heissenberger et al., Nucleic Acids Res., 2019, 47, 22: 11807–11825, doi: 10.1093/nar/gkz1043 | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene PRO | application note | ![]() |
|||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene PRO | publication | K. Estrada, JAMA, 2014, 311(22): 2305-2314; doi:10.1001/jama.2014.6511 | |||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | plasmid | stable transfection | Metafectene PRO | publication | R. Martınez-Marmol et al., Cell. Mol. Life Sci., 2016, 73:1515-1528; DOI 10.1007/s00018-015-2082-0 | |||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | stable transfection | Metafectene PRO | publication | Y. P. Abudu et al., J. Cell Biol., 2021, 220(8): e202009092, doi: 10.1083/jcb.202009092 | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | CRISPR | Metafectene PRO | publication | A. J. Jakobi et al., Nature Communications, 2020, 11: 440, doi.org/10.1038/s41467-020-14343-8 | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene PRO | publication | E. Bernardinelli et al., PLOSONE, doi.org/10.1371/journal.pone.0179591 | Link |